NCT06364150 Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction
| NCT ID | NCT06364150 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Seoul National Hospital |
| Condition | Acute Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-07-15 |
| Primary Completion | 2025-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 30 participants in total. It began in 2024-07-15 with a primary completion date of 2025-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the efficacy and safety of "Therapeutic Use of Autologous-Primed Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute Myocardial Infarction".
Eligibility Criteria
Inclusion Criteria: * 1\. Male and female aged ≥19 years and ≤ 80 years * 2\. A clinical diagnosis of acute myocardial infarction within 4 weeks from randomization * 3\. Successful percutaneous coronary intervention to the target lesion (TIMI flow grade 3 and residual stenosis \<30% at the target lesion) with a drug-eluting stent and/or drug-eluting balloon * 4\. Agreement to give written informed consent. Exclusion Criteria: 1. Patients with uncontrolled heart failure (Killip class ≥ grade 2, or left ventricular ejection fraction \<20%) 2. Patients with uncontrolled chest pain due to ischemia 3. Patients with uncontrolled arrythmia 4. Active malignancy, or incompletely treated malignancy 5. Active infectious disease 6. Uncontrolled hematologic disease, including coagulopathy or bleeding diathesis 7. Presence of non-cardiac comorbidity with life expectancy ≤1 year from randomization 8. Females with childbearing potential or breast-feeding 9. Refusal to give written informed consent 10. Other conditions that may result in protocol non-compliance by the committees
Contact & Investigator
Hyun Jai Cho, MD
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT06364150 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 80 Years, studying Acute Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06364150 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 30 participants.
Is NCT06364150 currently recruiting?
Yes, NCT06364150 is actively recruiting participants. Contact the research team at medikang@gmail.com for enrollment information.
Where is the NCT06364150 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06364150 clinical trial?
NCT06364150 is sponsored by Seoul National Hospital. The principal investigator is Hyun Jai Cho, MD at Seoul National University Hospital. The trial plans to enroll 30 participants.